Jørgensen, J., Servos, S., & Kefalas, P. The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease. MDPI AG.
Chicago Style (17th ed.) CitationJørgensen, Jesper, Spiros Servos, and Panos Kefalas. The Potential Price and Access Implications of the Cost-utility and Budget Impact Methodologies Applied by NICE in England and ICER in the US for a Novel Gene Therapy in Parkinson’s Disease. MDPI AG.
MLA (9th ed.) CitationJørgensen, Jesper, et al. The Potential Price and Access Implications of the Cost-utility and Budget Impact Methodologies Applied by NICE in England and ICER in the US for a Novel Gene Therapy in Parkinson’s Disease. MDPI AG.